U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07087938) titled 'Cannabichromene Safety in Rheumatoid Arthritis' on May 31, 2024.
Brief Summary: For this quantitative study, the investigators will collect data on human safety and side-effects of Cannabichromene (CBC) and whether CBC reduces blood inflammatory markers and Rheumatoid Arthritis (RA) disease activity. The participants will participate in an ABAB design with 2 doses of CBC across the A phases. They will attend 5 in-person clinic visits where they will have physical evaluations, complete self-report forms, and have blood drawn for the following tests: hs-CRP, ESR, IL-6, TNF, Complete Blood Count [CBC], and CMP.
Study Start Date: July ...